Curriculum Vitae Europass

Informazioni personali

Nome/cognome	**MAURO CELLI**
Indirizzo	
Recapiti telefonici	
Mobile	
E-mail	
Data di nascita	30.10.1960
Occupazione Settore professionale	Dipartimento di Pediatria e Neuropsichiatria Infantile – Azienda Policlinico Umberto I°-Università di Roma "Sapienza" – Viale Regina Elena, 324 – 00161 Rome

- Dirigente Medico Policlinico Umberto I di Roma,
- Referente Registro Malattie Rare Regione Lazio per il Presidio Regionale per le Osteodistrofie Congenite
- Responsabile Aziendale "Malattie Rare e Tumori rari" Policlinico Umberto I di Roma
- Componente Tavolo Tecnico per le malattie rare della Regione Lazio
- Titolare insegnamento di Pediatria Scuola Infermieristica "Sapienza" Università di Roma
- Titolare insegnamento quale cultore della materia in malattie rare nella Scuola di Specializzazione in Pediatria "Sapienza" Università di Roma
- Titolare insegnamento quale Cultore della materia in malattie rare nel Corso di Laurea di Medicina e Chirurgia "Sapienza" Università di Roma
- Docente Corso di Alta formazione in "Osteoporosi e Malattie Metaboliche della Scheletro" SIOMMS e "Sapienza" Università di Roma

Istruzione e formazione

1987

Laurea in Medicina e Chirurgia

	"Sapienza" Università di Roma 1991 Dottore di Ricerca in Fisiopatologia dell'assorbimento intestinale in età pediatrica La Sapienza Università di Roma 1991 Specializzazione in Pediatria La Sapienza Università di Roma
Madre lingua	Italiano
Altre lingue	Inglese, Francese
Capacità e competenze informatiche	Ottima competenza del sistema operativo Micorsoft Office, di Onconet, programma di cartella elettronica per pazienti Oncologici, Infinit, Galileo
Capacità e competenze organizzative	Sin dal 1995 Investigatore Principale in numerosi trial clinici
Altre informazioni	Relatore a diversi Congressi Nazionali e Internazionali
Pubblicazioni	Allegato

Roma 25,07,2016

Dott. Mauro Cerri

PUBLICATION LIST

1. *Serum creatine kinase isoenzimes in children with Osteogenesis Imperfecta*
   D'Eufemia P, Finocchiaro R, Zambrano A, Lodato V, Celli L, Finocchiaro S, Persiani P, Turchetti A, Celli M.
   Osteoporos. Int. 2016 (In Press)

2. *Osteogenesis imperfecta and rapid maxillary expansion: Report of 3 patients.*
   Ierardo G, Calcagnile F, Luzzi V, Ladniak B, Bossu M, Celli M, Zambrano A, Franchi L, Polimeni A.
   Am J Orthod Dentofacial Orthop. 2015 Jul;148(1):130-7.

3. *Osteochondritis dissecans of the lateral femoral condyle in a patient affected by osteogenesis imperfecta: a case report.*
   Persiani P, Di Domenica M, Martini L, Ranaldi FM, Zambrano A, Celli M, Villani C.
   J Pediatr Orthop B. 2015; 24:521-5

4. *Association between spondylolisthesis and L5 fracture in patients with Osteogenesis Imperfecta.*
   Persiani P, Graci J, de Cristo C, Noia G, Villani C, Celli M.
   Eur Spine J. 2015 Jan 1.

5. *Phenotypic variability in developmental coordination disorder: Clustering of generalized joint hypermobility with attention deficit/hyperactivity disorder, atypical swallowing and narrative difficulties.*
   Celletti C, Mari G, Ghibellini G, Celli M, Castori M, Camerota F.
   Am J Med Genet C Semin Med Genet. 2015 Mar;169C(1):117-22.

6. *Reliability of vertebral fractures assessment (VFA) in children with Osteogenesis Imperfecta*
   Diacinti D, Pisani D, D'Avanzo M, Celli M, Zambrano A, Stoppo M, Diacinti D, Roggini M, Todde F, D'Eufemia P, Pepe J, Minisola S.
   Calcif. Tissue Int. 2015; 96:307-12

7. *Serum brain-type creatine kinase increases in children with osteogenesis imperfecta during neridronate treatment.*
   D'Eufemia P, Finocchiaro R, Villani C, Zambrano A, Lodato V, Palombaro M, Properzi E, Celli M.
   Pediatr Res. 2014 May;75(5):626-30.

8. *Child abuse and osteogenesis imperfecta: how can they be still misdiagnosed? A case report.*
   D'Eufemia P, Palombaro M, Lodato V, Zambrano A, Celli M, Persiani P, De Bari MP, Sangiorgi L.
   Clin Cases Miner Bone Metab. 2012 Sep; 9(3):195-7.

9. *Management of pain and fatigue in the joint hypermobility syndrome (a.k.a. Ehlers-Danlos syndrome, hypermobility type): principles and proposal for a multidisciplinary approach.*
   Castori M, Morlino S, Celletti C, Celli M, Morrone A, Colombi M, Camerota F, Grammatico P.
   Am J Med Genet A. 2012 Aug;158A(8):2055-70.

10. *Ebstein's anomaly in a child with osteogenesis imperfecta type I.*
    D'Eufemia P, Celli M, Versacci P, Zambrano A, Lodato V, Persiani P, Sangiorgi L.
    Clin Cases Miner Bone Metab. 2011 May;8(2):50-1.

11. *Vitamin D deficiency rickets in five "at-risk" children.*
    D'Eufemia P, Parisi P, Celli M, Finocchiaro R, Roggini M, Raccio I, Zambrano A, Villa MP.
    Pediatr Int. 2012 Feb;54(1):152-5.

12. *Osteogenesis Imperfecta: the audiological phenotype lacks correlation with the genotype.*
    Swinnen FK, Coucke PJ, De Paepe AM, Symoens S, Malfait F, Gentile FV, Sangiorgi L, D'Eufemia P, Celli M, Garretsen TJ, Cremers CW, Dhooge IJ, De Leenheer EM.
    Orphanet J Rare Dis. 2011 Dec 29;6:88.

13. *Celiac disease and lamellar ichthyosis. Case study analysis and review of the literature.*
    Nenna R, D'Eufemia P, Celli M, Mennini M, Petrarca L, Zambrano A, Montuori M, La Pietra M, Bonamico M.
    Acta Dermatovenerol Croat. 2011;19(4):268-70. Review.

14. *Tyrosinemia type I: long-term outcome in a patient treated with doses of NTBC lower than recommended.*
    D'Eufemia P, Celli M, Tetti M, Finocchiaro R.
    Eur J Pediatr. 2011 Jun;170(6):819.

15. *Taurine deficiency in thalassemia major-induced osteoporosis treated with neridronate*
    D'Eufemia P, Finocchiaro R, Celli M, Raccio I, Zambrano A, Tetti M, Smacchia P, Iacobini M.
    Biomed. Pharmacother. 2010; 64:271-4

16. *Increased nitric oxide release by neutrophils of a patient with tyrosinemia type III.*
D'Eufemia P, Finocchiaro R, Celli M, Raccio I, Properzi E, Zicari A.
Biomed Pharmacother. 2009 Jun;63(5):359-61.

17. *Impairment of diastolic function in adult patients affected by osteogenesis imperfecta clinically asymptomatic for cardiac disease: casuality or causality?*
Migliaccio S, Barbaro G, Fornari R, Di Lorenzo G, Celli M, Lubrano C, Falcone S, Fabbrini E, Greco E, Zambrano A, Brama M, Prossomariti G, Marzano S, Marini M, Conti F, D'Eufemia P, Spera G.
Int J Cardiol. 2009 Jan 9;131(2):200-3.

18. *High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment.*
D'Eufemia P, Finocchiaro R, Celli M, Zambrano A, Tetti M, Villani C, Persiani P, Mari E, Zicari A.
Pediatr Res. 2008 Feb;63(2):203-6.

19. *Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.*
D'Eufemia P, Finocchiaro R, Zambrano A, Tetti M, Ferrucci V, Celli M.
Biomed Pharmacother. 2007 May; 61(4):235-40.

20. *Absence of severe recurrent infections in glycogen storage disease type 1b with neutropenia and neutrophil dysfunction.*
D'Eufemia P, Finocchiaro R, Celli M, Zambrano A, Tetti M, Ferrucci V, Lenti L
J. Inherit. Metab. Dis. 2007; 30:105

21. *Neutrophil glutamine deficiency in relation to genotype in children with cystic fibrosis.*
D'Eufemia P, Finocchiaro R, Celli M, Tote J, Ferrucci V, Zambrano A, Troiani P, Quattrucci S.
Pediatr Res. 2006 Jan; 59(1):13-6.

22. *Fatty acid profile of oesophageal mucosa in children with gastro-oesophageal reflux disease.*
D'Eufemia P, Celli M, Finocchiaro R, Troiani P, Tote J, Giardini O, Corrado G.
Dig Liver Dis. 2003 Oct;35(10):694-700.

23. *Increased taurine content in esophageal mucosa of children affected by gastroesophageal reflux.*
D'Eufemia P, Corrado G, Finocchiaro R, Celli M, Cavaliere M, Troiani P, Tote J, Cardi E, Giardini O.
Dig Dis Sci. 2001 Apr;46(4):808-14.

24. *Low-dosage immunoglobulins for an infant with hypogammaglobulinemia, maple syrup urine disease, and parvovirus B19-associated aplastic crisis.*
D'Eufemia P, Nigro G, Celli M, Finocchiaro R, Iannetti P, Giardini O.
J Pediatr Hematol Oncol. 2000 Sep-Oct;22(5):485-7.

25. *Sandifer's syndrome in a breast-fed infant.*
Corrado G, Cavaliere M, D'Eufemia P, Pelliccia A, Celli M, Porcelli M, Giardini O, Cardi E.
Am J Perinatol. 2000;17(3):147-50.

26. *Determination of urinary orotic acid and uracil by capillary zone electrophoresis.*
Salerno C, D'Eufemia P, Celli M, Finocchiaro R, Crifò C, Giardini O.
J Chromatogr B Biomed Sci Appl. 1999 Oct 29;734(1):175-8.

27. *Effect of D-ribose on purine synthesis and neurological symptoms in a patient with adenylosuccinase deficiency.*
Salerno C, D'Eufemia P, Finocchiaro R, Celli M, Spalice A, Iannetti P, Crifò C, Giardini O.
Biochim Biophys Acta. 1999 Jan 6;1453(1):135-40.

28. *Usefulness of cyanide-nitroprusside test in detecting incomplete recessive heterozygotes for cystinuria: a standardized dilution procedure.*
Finocchiaro R, D'Eufemia P, Celli M, Zaccagnini M, Viozzi L, Troiani P, Mannarino O, Giardini O.
Urol Res. 1998;26(6):401-5.

29. *[Jejunal enteral feeding in a severe case of reflux esophagitis in an infant with Pierre-Robin syndrome].*
Chiaretti M, Fracassi RM, Ferrante P, Scalercio F, Principessa L, Caropreso E, Celli M, Finocchiaro R.
Minerva Pediatr. 1998 May;50(5):175-8.

30. *Effect of D-ribose administration to a patient with inherited deficit of adenylosuccinase.*
Salerno C, Celli M, Finocchiaro R, D'Eufemia P, Iannetti P, Crifò C, Giardini O.
Adv Exp Med Biol. 1998;431:177-80.

31. *Erythrocyte and plasma levels of glutamate and aspartate in children affected by migraine.*
D'Eufemia P, Finocchiaro R, Lendvai D, Celli M, Viozzi L, Troiani P, Turri E, Giardini O.
Cephalalgia. 1997 Oct;17(6):652-7.

32. *Abnormal intestinal permeability in children with autism.*
D'Eufemia P, Celli M, Finocchiaro R, Pacifico L, Viozzi L, Zaccagnini M, Cardi E, Giardini O.
Acta Paediatr. 1996 Sep;85(9):1076-9.

33. *Rapid gas-chromatographic assay of lactulose and mannitol for estimating intestinal permeability.*
Celli M, D'Eufemia P, Dommarco R, Finocchiaro R, Aprigliano D, Martino F, Cardi E, Giardini O.
Clin Chem. 1995 May;41(5):752-6.

34. *Low serum tryptophan to large neutral amino acids ratio in idiopathic infantile autism.*
D'Eufemia P, Finocchiaro R, Celli M, Viozzi L, Monteleone D, Giardini O.
Biomed Pharmacother. 1995;49(6):288-92.

35. *Immunological abnormalities in a patient with tyrosinaemia type III.*
D'Eufemia PD, Finocchiaro R, Celli M, Viozzi L, Giardini O.
J Inherit Metab Dis. 1995;18(3):355-6.

36. *Late onset of cystinuria in a case of gyrate atrophy.*
D'Eufemia P, Giardini O, Prisco F, Celli M, Finocchiaro R, Martino F, Stoppoloni G.
J Inherit Metab Dis. 1993;16(5):904-5..

37. *Child with manifestations of dermotrichic syndrome and ichthyosis follicularis-alopecia-photophobia (IFAP) syndrome.*
Martino F, D'Eufemia P, Pergola MS, Finocchiaro R, Celli M, Giampà G, Frontali M, Giardini O.
Am J Med Genet. 1992 Sep 15;44(2):233-6.

38. *[Atherosclerosis and pediatrics. Role of nutrition of healthy children].*
Corrado G, Martino F, D'Eufemia P, Negrini R, Celli M.
Clin Ter. 1990 Nov 15;135(3):201-7. Italian.